Company Monitoring Page for uniQure

latest headlines for company on cafepharma

Gene therapy for Fabry: early stages, promising results
BioPharma Dive
Thu, 07/22/21 - 10:02 pm
Tags:
gene therapy, Fabry disease, uniQure, Avrbio, Freeline Therapeutics, Sangamo Therapeutics
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Motley Fool
Sun, 07/11/21 - 11:13 pm
Tags:
clinical trials, Novartis, Biogen, SAGE Therapeutics, uniQure, Pfizer, Roche
Biopharma takeovers dry up
EP Vantage
Mon, 07/5/21 - 09:50 pm
Tags:
M&A, MorphoSys, Constellation Pharmaceuticals, Sanofi, Tidal Therapeutics, uniQure, Corlieve Therapeutics, Strongbridge Biopharma, Xerix Pharmaceuticals, Novellus Therapeutics, Brooklyn Immunotherapeutics
With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline
Endpoints
Tue, 06/22/21 - 10:37 pm
Tags:
uniQure, M&A, Corlieve Therapeutics, AMT-260, gene therapy, temporal lobe epilepsy
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
Mon, 06/21/21 - 11:11 am
Tags:
clinical trials, Merck, Ridgeback Biotherapeutics, COVID-19, Intellia Therapeutics, transthyretin amyloidosis, Arcus Biosciences, Gilead Sciences, lung cancer, Sanofi, GSK, vaccines, uniQure, Huntington's disease, Mirati Therapeutics, gene editing, Seres Therapeutics, ulcerative colitis, Sarepta Therapeutics, Duchenne Muscular Dystrophy
UniQure moves Huntington's gene therapy to next phase of key trial
BioPharma Dive
Thu, 05/27/21 - 11:54 pm
Tags:
uniQure, Huntington's disease, clinical trials, gene therapy, AMT-130
FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump
Fierce Biotech
Mon, 04/26/21 - 10:46 am
Tags:
uniQure, hemophilia, gene therapy, FDA
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
Benzinga
Mon, 03/29/21 - 10:36 am
Tags:
uniQure, gene therapy, hemophilia B, etranacogene dezaparvovec, clinical trials
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
Thu, 01/28/21 - 11:18 pm
Tags:
hemophilia, hemophilia A, hemophilia B, gene therapy, Biomarin, uniQure
UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find
Fierce Biotech
Mon, 12/21/20 - 11:09 am
Tags:
uniQure, CSL, FDA, clinical trials, hemophilia B, gene therapy, etranacogene dezaparvovec
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
Mon, 12/7/20 - 10:32 am
Tags:
ASH2020, uniQure, hemophilia A, Sangamao, gene therapy, Biomarin
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
Seeking Alpha
Wed, 06/24/20 - 11:29 pm
Tags:
uniQure, CSL, hemophilia B, etranacogene dezaparvovec
UniQure gets out the gate first in race for Huntington's gene therapy
BioPharma Dive
Sat, 06/20/20 - 09:41 pm
Tags:
uniQure, clinical trials, Huntington's disease, AMT-130
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Thu, 12/12/19 - 10:52 am
Tags:
Biomarin, hemophilia, hemophilia A, gene therapy, valoctocogene roxaparvovec, uniQure, hemophilia B, etranadez
UniQure presses go on Huntington’s gene therapy trial
Pharmaforum
Mon, 10/28/19 - 10:41 am
Tags:
uniQure, Huntington's disease, gene therapy, AMT-130, clinical trials
Why Novo Nordisk should buy Uniqure
EP Vantage
Fri, 10/11/19 - 10:31 am
Tags:
Novo Nordisk, gene editing, hemophilia, uniQure, Bluebird Bio
UniQure stays a step ahead in hemophilia B
Biopharma Dive
Tue, 09/3/19 - 12:32 pm
Tags:
uniQure, gene therapy, hemophilia B, clinical trials, AMT-061
Why biotech companies are often at the whim of things they cannot control, in one chart
Stat
Wed, 07/31/19 - 11:47 pm
Tags:
uniQure
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Mon, 07/1/19 - 10:32 am
Tags:
Retrophin, Karyopharm, Celyad, uniQure, Sangamo Therapeutics, Catalyst Biosciences, Novo Nordisk, Reata Pharmaceuticals, Vertex Pharmaceuticals, Bellicum, Gilead Sciences, Jaguar Health, TRACON Pharmaceuticals, FibroGen, Aslan Pharma, ObsEva, Sorrento Therapeutics
Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report
Endpoints
Sun, 06/16/19 - 11:19 pm
Tags:
uniQure, M&A, gene therapy

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.